Expert Insights on Oncology

Oncology is the field of medicine dealing with tumors (cancer), including their biology, prevention, diagnosis, and treatment. Cancer biology focuses on the mechanisms for abnormal cell growth and tumor metastasis; diagnosis involves biopsy, endoscopy, radiological imaging, nuclear medicine, and blood tests for tumor markers; prevention includes genetic testing, education, and screening; therapies like surgery, chemotherapy, and radiation therapy aim to inhibit tumor development.

Gerson Lehrman Group Council Members are available to discuss Oncology via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist, INTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Jeffrey Bubis What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Partner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist, INTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Jeffrey Bubis What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Partner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Taral Patel, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC

Taral Patel What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

OncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

Charles Bennett, Radiation Oncologist , ROBERT BOISSONEAULT ONCOLOGY INSTITUTE

Charles Bennett What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Radiation Oncologist ROBERT BOISSONEAULT ONCOLOGY INSTITUTE

Federico Cappuzzo, Professor & Director of Medical Oncology , Ospedali Riuniti Livorno

Federico Cappuzzo What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Professor & Director of Medical Oncology Ospedali Riuniti Livorno

Browse all 364 Leading Experts

Study Groups

Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry

Study Group Name No. Members
Oncology Reimbursement Experts (US) 183
Oncology Devices Distributors 39
Oncology Reimbursement Experts (US) 183
Oncology Devices Distributors 39
Oncology Physicians who Treat CID (US) 28

Browse all 981 Study Groups

Recent Live Meetings

Interactive roundtables, private visits, and small scale seminars are types of GLG Live Meetings

November 20, 2009 | San Francisco

Seminar: Issues in Using PFS when Evaluating Oncology Products with Dr. Fleming (San Francisco)

November 12, 2009 | Boston

Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (Boston)

November 13, 2009 | New York

Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (New York)

Browse all 384 Live Meetings

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Donald Fleming, Director of the Cancer Care Center , DAVIS HEALTH SYSTEM, INC.

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Donald Fleming, Director of the Cancer Care Center , DAVIS HEALTH SYSTEM, INC.

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Donald Fleming, Director of the Cancer Care Center , DAVIS HEALTH SYSTEM, INC.

4SC Phase II trial of the HDAC inhibitor 4SC-201

August 28, 2009

GLG Expert Contributor

Molecure for rare diseases?

August 18, 2009

GLG Expert Contributor

Browse all 8743 GLG News Analyses

Contact Gerson Lehrman Group to engage a Oncology expert